Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
In Vivo ; 34(4): 2037-2041, 2020.
Article in English | MEDLINE | ID: mdl-32606179

ABSTRACT

Schwannomas occurring in the hepatoduodenal ligament are extremely rare, with only four cases reported. Here, we describe a case of a 30-mm schwannoma that originated in the hepatoduodenal ligament of a 38-year-old female found during a periodic medical check-up. Magnetic resonance imaging demonstrated a tumor in the hepatoduodenal ligament. Following an ultrasound-guided microbiopsy, histological examination showed solitary fibrous tumor or schwannomas in the liver or originating from the hepαtoduodenal ligament. The relationship between the tumor and associated organs was confirmed intraoperatively, and the tumor was removed safely in its entirety using indocyanine green. The postoperative histopathological examination revealed the presence of a schwannoma with typical characteristics. To our knowledge, this is the first case of hepatoduodenal ligament schwannoma treated by laparoscopic surgery using indocyanine green fluorescence imaging.


Subject(s)
Laparoscopy , Neurilemmoma , Adult , Female , Fluorescence , Humans , Indocyanine Green , Ligaments/diagnostic imaging , Ligaments/surgery , Liver , Neurilemmoma/diagnostic imaging , Neurilemmoma/surgery
2.
J Viral Hepat ; 19(4): 254-62, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22404723

ABSTRACT

Hepatitis C virus (HCV) infects and associates with B cells, leading to abnormal B-cell activation and development of lymphoproliferative and autoimmune disorders. This immune perturbation may in turn be associated with the resistance of HCV against the host immune system. The objective of this study was to analyse the effects of HCV infection of B cells on the efficacy of interferon (IFN)-based therapy. The study enrolled 102 patients with chronic hepatitis C who were treated with pegylated IFN plus ribavirin. HCV RNA titres in B cells were compared in patients with rapid viral responder (RVR) vs non-RVR, sustained viral responder (SVR) vs non-SVR and null viral responder (NVR) vs VR. The levels of HCV RNA in B cells were significantly higher in non-RVR, non-SVR and NVR groups. Association between the therapy outcome and the positive B-cell HCV RNA was also investigated in relation to other known viral and host factors. Multivariable analyses showed that the positive B-cell HCV RNA and the minor single-nucleotide polymorphism near the IL28B gene (rs8099917) were independent factors associated with NVR in patients infected with HCV genotype 1. When these two factors were combined, the sensitivity, specificity, positive and negative predictive values for NVR were 92.3%, 98.2%, 92.3% and 98.2%, respectively. Genotype 1 and the presence of one or no mutations in the IFN-sensitivity determining region were associated with higher levels of B-cell HCV RNA. B-cell-tropic HCV appears to have an IFN-resistant phenotype. B-cell HCV RNA positivity is a predictive factor for resistance to IFN-based therapy.


Subject(s)
Antiviral Agents/administration & dosage , B-Lymphocytes/virology , Drug Resistance, Viral , Hepacivirus/drug effects , Hepacivirus/physiology , Interferons/administration & dosage , Viral Tropism , Adult , Aged , Female , Genotype , Hepacivirus/genetics , Hepacivirus/isolation & purification , Humans , Interleukins/genetics , Male , Middle Aged , Polymorphism, Single Nucleotide , RNA, Viral/analysis , RNA, Viral/genetics , Ribavirin/administration & dosage , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...